Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target

Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target

Needham analyst Serge Belanger upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Hold to Buy and maintains $14 price target.

byBenzinga Newsdesk

February 22, 2023

1 minute read

Needham analyst Serge Belanger upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Hold to Buy and maintains $14 price target.

Barrick Targets Peruvian Expansion Amidst Record Gold Prices

By Stjepan Kalinic

April 5, 10:50 AM

Barrick Gold Corp is expanding in Latin America to meet demand, targeting Puno, Peru. Its 2023 success and gold price surge coincide.

CGDXF

Analyst Ratings

What 4 Analyst Ratings Have To Say About Entegris

By Benzinga Insights

July 20, 5:35 PM

Within the last quarter, Entegris (NASDAQ:ENTG) has observed the following analyst ratings:

ENTG

Why Mullen Automotive Stock Is Charging Higher

By Erica Kollmann

Yesterday, 1:43 PM

Mullen Automotive Inc. (NASDAQ: MULN) shares are trading higher after the company announced it received a favorable decision from the Nasdaq Hearings Panel.

MULN

Piper Sandler Downgrades Unity Software to Neutral, Lowers Price Target to $34

By Benzinga Newsdesk

July 14, 4:34 AM

Piper Sandler analyst Brent Bracelin downgrades Unity Software (NYSE:U) from Overweight to Neutral and lowers the price target from $55 to $34.

Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target

Related Posts

Barrick Targets Peruvian Expansion Amidst Record Gold Prices

What 4 Analyst Ratings Have To Say About Entegris

Why Mullen Automotive Stock Is Charging Higher

Piper Sandler Downgrades Unity Software to Neutral, Lowers Price Target to $34